A detailed history of Two Sigma Investments, LP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 159,154 shares of DYN stock, worth $5.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
159,154
Previous 8,912 1685.84%
Holding current value
$5.38 Million
Previous $253,000 2119.76%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $3.55 Million - $5.35 Million
150,242 Added 1685.84%
159,154 $5.62 Million
Q1 2024

May 15, 2024

BUY
$13.06 - $29.18 $116,390 - $260,052
8,912 New
8,912 $253,000
Q3 2023

Nov 14, 2023

SELL
$8.6 - $12.18 $69,660 - $98,658
-8,100 Reduced 24.92%
24,400 $218,000
Q2 2023

Aug 14, 2023

SELL
$8.53 - $14.28 $1.08 Million - $1.81 Million
-126,487 Reduced 79.56%
32,500 $365,000
Q1 2023

May 15, 2023

BUY
$10.88 - $15.0 $39,581 - $54,570
3,638 Added 2.34%
158,987 $1.83 Million
Q4 2022

Feb 14, 2023

BUY
$9.37 - $13.8 $1.3 Million - $1.91 Million
138,325 Added 812.53%
155,349 $1.8 Million
Q3 2022

Nov 14, 2022

BUY
$7.2 - $15.17 $122,572 - $258,254
17,024 New
17,024 $216,000
Q2 2022

Aug 15, 2022

SELL
$4.36 - $10.5 $116,507 - $280,581
-26,722 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$6.52 - $12.27 $658,565 - $1.24 Million
-101,007 Reduced 79.08%
26,722 $258,000
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $172,702 - $233,416
14,525 Added 12.83%
127,729 $1.52 Million
Q3 2021

Nov 15, 2021

BUY
$15.6 - $21.46 $1.77 Million - $2.43 Million
113,204 New
113,204 $1.84 Million
Q2 2021

Aug 16, 2021

SELL
$15.94 - $22.33 $414,440 - $580,580
-26,000 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$14.0 - $29.3 $364,000 - $761,800
26,000 New
26,000 $404,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.75B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.